# Polaryx Therapeutics, Inc.: financial statements, quarterly

PLYX · Nasdaq · CIK 2075320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/plyx.md) · [Financials](/companies/plyx/financials.md) · [Filings](/companies/plyx/filings.md) · [Insiders](/companies/plyx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/plyx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $k | [4,716](/filings/0001213900-26-056973.md) | [476](/filings/0001213900-26-089118.md) | [679](/filings/0001213900-26-056973.md) | [719](/filings/0001213900-26-089118.md) |
| Operating income | $k | [(5,052)](/filings/0001213900-26-056973.md) | [(884)](/filings/0001213900-26-089118.md) | [(1,958)](/filings/0001213900-26-056973.md) | [(1,380)](/filings/0001213900-26-089118.md) |
| Net income | $k | [(5,052)](/filings/0001213900-26-056973.md) | [(1,008)](/filings/0001213900-26-089118.md) | [(2,544)](/filings/0001213900-26-056973.md) | [(1,380)](/filings/0001213900-26-089118.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001213900-26-056973.md) | [(0.02)](/filings/0001213900-26-089118.md) | [(0.05)](/filings/0001213900-26-056973.md) | [(0.03)](/filings/0001213900-26-089118.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0001213900-26-056973.md) | [(0.02)](/filings/0001213900-26-089118.md) | [(0.05)](/filings/0001213900-26-056973.md) | [(0.03)](/filings/0001213900-26-089118.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-12-31) | period not labelled (2025-01-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [4.6](/filings/0001213900-26-033064.md) | [0.3](/filings/0001213900-26-089118.md) | not reported | not reported | [5.1](/filings/0001213900-26-089118.md) | [3.1](/filings/0001213900-26-056973.md) | [11.5](/filings/0001213900-26-089118.md) |
| Current assets | $m | not reported | [5.0](/filings/0001213900-26-033064.md) | not reported | not reported | not reported | [5.2](/filings/0001213900-26-089118.md) | [3.5](/filings/0001213900-26-056973.md) | [11.8](/filings/0001213900-26-089118.md) |
| Total assets | $m | not reported | [5.0](/filings/0001213900-26-033064.md) | not reported | not reported | not reported | [5.2](/filings/0001213900-26-089118.md) | [3.5](/filings/0001213900-26-056973.md) | [11.8](/filings/0001213900-26-089118.md) |
| Current liabilities | $m | not reported | [0.3](/filings/0001213900-26-033064.md) | not reported | not reported | not reported | [0.6](/filings/0001213900-26-089118.md) | [1.0](/filings/0001213900-26-056973.md) | [0.9](/filings/0001213900-26-089118.md) |
| Total liabilities | $m | not reported | [0.3](/filings/0001213900-26-033064.md) | not reported | not reported | not reported | [0.6](/filings/0001213900-26-089118.md) | [1.0](/filings/0001213900-26-056973.md) | [0.9](/filings/0001213900-26-089118.md) |
| Shareholders' equity | $m | [1.3](/filings/0001213900-26-033064.md) | [4.7](/filings/0001213900-26-089118.md) | not reported | [4.3](/filings/0001213900-26-089118.md) | [3.2](/filings/0001213900-26-089118.md) | [4.6](/filings/0001213900-26-089118.md) | [2.5](/filings/0001213900-26-089118.md) | [10.9](/filings/0001213900-26-089118.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(709)](/filings/0001213900-26-056973.md) | [(858) d](/filings/0001213900-26-089118.md) | [(2,063)](/filings/0001213900-26-056973.md) | [(1,369) d](/filings/0001213900-26-089118.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [44.3](/filings/0001213900-26-056973.md) | [44.7](/filings/0001213900-26-089118.md) | [47.2](/filings/0001213900-26-056973.md) | [48.3](/filings/0001213900-26-089118.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,845,993 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-089118.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.